title: KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.
abstract: Our aim was to evaluate the killer cell immunoglobulin-like receptors (KIRs) as a marker for the development of thrombocytopenia secondary to Peg-interferon (IFN) therapy in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients. Patients were naive to HCV treatment, receiving a first course of Peg-IFN/Ribavirin combination therapy. Total platelet count (cells ml-1) was determined at each visit, determining platelet decline from baseline to weeks 1, 2, 4, 8 and 12 after starting therapy. The end point of the study was development of thrombocytopenia, defined as a platelet count of <1 50 000 cells ml-1. Fifty-eight HIV/HCV co-infected patients were included in the study, of whom 20 (34.4%) developed thrombocytopenia. The absence of KIR2DS2 was associated with higher and faster rate of thrombocytopenia (54.2% vs 22.5%; P=0.012; 6.6 vs 10.3 weeks; P=0.008). The absence of KIR2DS2 was associated with a greater decline in platelet count and development of thrombocytopenia during Peg-IFN treatment in HIV/HCV co-infected patients.
authors.affiliation: Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Rivero-Juarez
authors.affiliation: Immunology Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Gonzalez
authors.affiliation: Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Frias
authors.affiliation: Immunology Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Manzanares-Martín
authors.affiliation: Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Rodriguez-Cano
authors.affiliation: Service de Medicina Tropical, Hospital de Poniente, El Ejido, Almería, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Perez-Camacho
authors.affiliation: Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Gordon
authors.affiliation: Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Cuenca
authors.affiliation: Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Camacho
authors.affiliation: Infectious Diseases and Clinical Microbiology Unit, Hospital Universitario de Valme, Seville, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Pineda
authors.affiliation: Cellular Biology, Physiology and Immunology Department, Universidad de Córdoba, Córdoba, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Peña
authors.affiliation: Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Córdoba, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Rivero
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D060085:Coinfection / Q000188:drug therapy / Q000378:metabolism; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D010976:Platelet Count / Q000379:methods; D054340:Receptors, KIR / Q000378:metabolism*; D012254:Ribavirin / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; C433932:KIR2DS2 protein, human; D054340:Receptors, KIR; D012254:Ribavirin